Microtubule targeting agents often disrupt intracellular trafficking via microtubules [34,35], and prolonged treatment with T-DM1, but not with trastuzumab, caused defective intracellular trafficking of HER2 in a preclinical breast cancer model [18]. The gene discussed is ERBB2; the disease is breast cancer.